| Characteristic . | LTNP-C (n = 100) . | Non-LTNP-C (n = 40) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 69 (69) | 20 (50) | .037; 2.226 (1.051–4.716) | .040; 2.467 (1.040–5.852) |
| Age at HIV diagnosis (years) | 26.2 [22.1–31.8] | 29.9 [25.0–34.1] | .038; .950 (.904–.997) | .102; .957 (.908–1.009) |
| Interferon-lambda 4 TT/TT genotypea | 42 (44) | 26 (65) | .029; .427 (.198–.918) | .036; .401 (.171–.942) |
| HLA-B*27b,c | 18 (18) | 7 (18) | .982; .989 (.375–2.607) | |
| HLA-B*57b,c | 29 (29) | 5 (13) | .054; 2.770 (.981–7.824) | .044; 3.056 (1.029–9.069) |
| HLA-B*35b,c | 10 (10) | 7 (18) | .194; .498 (.174–1.426) | |
| HLA-B*08b,c | 5 (5) | 2 (5) | .964; .962 (.178–5.188) |
| Characteristic . | LTNP-C (n = 100) . | Non-LTNP-C (n = 40) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 69 (69) | 20 (50) | .037; 2.226 (1.051–4.716) | .040; 2.467 (1.040–5.852) |
| Age at HIV diagnosis (years) | 26.2 [22.1–31.8] | 29.9 [25.0–34.1] | .038; .950 (.904–.997) | .102; .957 (.908–1.009) |
| Interferon-lambda 4 TT/TT genotypea | 42 (44) | 26 (65) | .029; .427 (.198–.918) | .036; .401 (.171–.942) |
| HLA-B*27b,c | 18 (18) | 7 (18) | .982; .989 (.375–2.607) | |
| HLA-B*57b,c | 29 (29) | 5 (13) | .054; 2.770 (.981–7.824) | .044; 3.056 (1.029–9.069) |
| HLA-B*35b,c | 10 (10) | 7 (18) | .194; .498 (.174–1.426) | |
| HLA-B*08b,c | 5 (5) | 2 (5) | .964; .962 (.178–5.188) |
Qualitative data are number (%) of individuals and quantitative data are median (interquartile range). Significant values are shown in bold.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; LTNP-C, long-term nonprogressor HIV-1 controller; OR, odds ratio.
aData were available for 135 patients (95 LTNP-Cs and 40 non-LTNP-Cs).
bData were available for 133 patients (96 LTNP-Cs and 37 non-LTNP-Cs).
cDominant model was applied. There were no homozygous patients for HLA-B*57.
| Characteristic . | LTNP-C (n = 100) . | Non-LTNP-C (n = 40) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 69 (69) | 20 (50) | .037; 2.226 (1.051–4.716) | .040; 2.467 (1.040–5.852) |
| Age at HIV diagnosis (years) | 26.2 [22.1–31.8] | 29.9 [25.0–34.1] | .038; .950 (.904–.997) | .102; .957 (.908–1.009) |
| Interferon-lambda 4 TT/TT genotypea | 42 (44) | 26 (65) | .029; .427 (.198–.918) | .036; .401 (.171–.942) |
| HLA-B*27b,c | 18 (18) | 7 (18) | .982; .989 (.375–2.607) | |
| HLA-B*57b,c | 29 (29) | 5 (13) | .054; 2.770 (.981–7.824) | .044; 3.056 (1.029–9.069) |
| HLA-B*35b,c | 10 (10) | 7 (18) | .194; .498 (.174–1.426) | |
| HLA-B*08b,c | 5 (5) | 2 (5) | .964; .962 (.178–5.188) |
| Characteristic . | LTNP-C (n = 100) . | Non-LTNP-C (n = 40) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 69 (69) | 20 (50) | .037; 2.226 (1.051–4.716) | .040; 2.467 (1.040–5.852) |
| Age at HIV diagnosis (years) | 26.2 [22.1–31.8] | 29.9 [25.0–34.1] | .038; .950 (.904–.997) | .102; .957 (.908–1.009) |
| Interferon-lambda 4 TT/TT genotypea | 42 (44) | 26 (65) | .029; .427 (.198–.918) | .036; .401 (.171–.942) |
| HLA-B*27b,c | 18 (18) | 7 (18) | .982; .989 (.375–2.607) | |
| HLA-B*57b,c | 29 (29) | 5 (13) | .054; 2.770 (.981–7.824) | .044; 3.056 (1.029–9.069) |
| HLA-B*35b,c | 10 (10) | 7 (18) | .194; .498 (.174–1.426) | |
| HLA-B*08b,c | 5 (5) | 2 (5) | .964; .962 (.178–5.188) |
Qualitative data are number (%) of individuals and quantitative data are median (interquartile range). Significant values are shown in bold.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; LTNP-C, long-term nonprogressor HIV-1 controller; OR, odds ratio.
aData were available for 135 patients (95 LTNP-Cs and 40 non-LTNP-Cs).
bData were available for 133 patients (96 LTNP-Cs and 37 non-LTNP-Cs).
cDominant model was applied. There were no homozygous patients for HLA-B*57.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
